Pinealon

Overview

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR). It comes from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and belongs to the family of "short peptide bioregulators" / "cytogens" promoted by that group. It is marketed and discussed with a nootropic and neuroprotective framing.

The chemistry is well defined: PubChem lists it under CID 10273502 with molecular formula C15H26N6O8 and molecular weight ~418.4 g/mol, and chemical suppliers report the CAS number 175175-23-2. The biology, by contrast, is where caution is required. The proposed mechanism — that this very small peptide enters the cell nucleus and binds specific DNA sequences to steer transcription of neuroprotective and antioxidant genes — is supported mainly by in-vitro and animal work, and the human evidence is limited, older, largely Russian-language, single-group, and independently unconfirmed.

Pinealon is often grouped with other compounds from the same school, such as Epitalon, and with other nootropic neuropeptides such as Selank and Semax. As with those compounds, the central thing to understand is the gap between confident mechanistic claims and thin, non-independent human evidence. It is not an approved medicine anywhere.

Chemistry and structure

Pinealon is a linear tripeptide (three amino acids):

Glu-Asp-Arg (one-letter code: EDR)

The molecule carries two acidic residues (Glu, Asp) and one basic residue (Arg). Note the CAS number is consistently reported by chemical suppliers (MedChemExpress, BOC Sciences) but was not confirmed on the PubChem record retrieved, so it is reported here rather than treated as fully authoritative.

Mechanism of action

The mechanisms below are best read as proposed pathways, most of them from a single research school and grounded in cell and animal models rather than controlled human pharmacology. Each claim is tagged with its evidence level.

• Nuclear penetration and DNA binding. The small tripeptide is reported to penetrate the cell cytoplasm and nucleus — fluorescently-labelled EDR was tracked into the nucleus within minutes — and to bind specific promoter DNA sequences (e.g. d(CCTGCC)₂, d(CCAGC)₂) to regulate gene expression and protein synthesis. [In vitro / Hypothesis] (Molecules, 2021 — PMC7795577)
• Upregulation of antioxidant genes. EDR is reported to increase expression of the antioxidant enzyme genes SOD2 and GPX1 and of serotonin-pathway TPH1, and to raise PPARA/PPARG expression. [In vitro] (PMC7795577)
• Anti-apoptotic / anti-oxidative shift. EDR is reported to reduce pro-apoptotic caspase-3 and p53, lower reactive oxygen species, and modify ERK1/2 MAPK signalling timing in neurons under oxidative / hyperhomocysteinemia stress. [In vitro / Animal] (PMC7795577)
• Structural / cognitive effects in disease models. EDR is reported to restore dendritic spine density and improve Morris water-maze learning in Alzheimer-model rodents. [Animal] (PMC7795577)

Research and evidence

The evidence base is preclinical-heavy, older, and dominated by the originating Khavinson group, with no independent replication located.

Human evidence. There are no well-established, independent human clinical trials of Pinealon. The reported human data are limited, older, and essentially from the originating St. Petersburg group. A 2021 review states that EDR peptide has been examined in "elderly patients with cognitive impairment and consequences of traumatic brain injury" with reported memory/cognitive improvement [Human], but the primary trials are small, not blinded by modern standards, largely Russian-language, and not confirmed by any registered independent RCT. No FDA/EMA clinical-efficacy evaluation exists. No primary trial citations (author, year, journal, sample size, design) were retrieved beyond that review's summary, so human efficacy should be treated as unproven at the primary-trial level.

Status and regulation

Pinealon is not FDA- or EMA-approved for any indication. No published FDA/EMA evaluation, label, or marketing authorisation was found. It is distributed as "research use only" material by chemical/peptide vendors.

As with any unapproved peptide, it becomes an unauthorised medicinal product the moment it is intended for human use; "no specific ban found" is not affirmative permission.

WADA status: Not established. No primary WADA source lists Pinealon. Vendor or blog claims that it is "prohibited under S0" are inference from its non-approved status, not a WADA assertion, and are not recorded here as sourced. Athletes subject to anti-doping rules should consult current WADA guidance directly rather than assume a classification.

Safety

• There is no FDA/EMA document, label, or toxicology dossier for Pinealon, so its human safety profile is not established in primary regulatory sources.
• A lack of reported adverse events reflects a lack of rigorous study, not a demonstration of safety.
• Material sold as "Pinealon" is a research reagent; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• Because it is used as an injectable peptide in research and unregulated contexts, the usual risks of non-sterile injectable products also apply.

Legal status

Pinealon is best described by its regulatory classification, not by any notion of "legal for human use." It is sold as a research reagent / "research use only" chemical and is not approved by the FDA or EMA. No specific prohibition was found in the sources consulted — but "no specific ban" is not affirmative permission, and the compound becomes an unauthorised medicinal product the moment it is intended for human use. Legality and WADA sport-eligibility are separate axes; neither implies the other.

This is not legal advice, and legal status varies by country and changes over time. Check the rules in your own jurisdiction. Status current as of the July 2026 research date.

How it compares

• Epitalon — another ultra-short peptide from the same Khavinson bioregulator school, framed around anti-aging/telomeres. It shares Pinealon's central caveat: bold mechanistic claims resting on older, mostly single-group, largely preclinical evidence with little independent replication.
• Selank and Semax — Russian-developed nootropic neuropeptides studied for anxiety/cognition. Like Pinealon, their human evidence is concentrated in Russian-language literature and is not established by independent, modern, registered trials.

Common misconceptions

• "Pinealon is a proven nootropic that improves human memory." Not established. The human reports are limited, older, single-group, largely Russian-language, and unreplicated [Human]; there are no well-established independent clinical trials.
• "It's clinically shown to protect neurons and reverse Alzheimer's changes." The neuroprotection, dendritic-spine and maze-learning findings are in cells and rodent disease models [In vitro/Animal], not proof of a clinical effect in people.
• "A tiny peptide obviously can't reach the nucleus and change gene expression." The originating group reports exactly that in vitro [In vitro/Hypothesis] — but reporting it in cell systems is not the same as establishing it as the physiological mechanism in humans.
• "It survives digestion, so oral dosing works." Oral-bioavailability claims come from secondary/marketing sources and were not verified from any primary pharmacokinetic study.
• "It's WADA-banned under S0." No primary WADA source lists Pinealon. That claim is inference from its unapproved status, not a WADA assertion.

Russian research

Most of the evidence for pinealon (the tripeptide Glu-Asp-Arg, also written EDR) comes from a single Russian school — Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and its immediate research network — with one linked behavioral group in Rostov; it is surfaced here for completeness and framed honestly, because almost none of it has been independently replicated outside Russia.

The mechanistic and preclinical base is real but narrow:

• [In vitro] In cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, pinealon produced a dose-dependent restriction of reactive-oxygen-species accumulation and reduced cell death; the protective effect plateaued at low concentrations while cell-cycle changes continued at higher doses, which the authors interpreted as possible direct interaction with cellular genetic material (Khavinson et al., Rejuvenation Research, 2011; PMID 21978084; DOI 10.1089/rej.2011.1172). Single study, originating group, cell-culture only.
• [In vitro] Short peptides including pinealon penetrated HeLa cell nuclei and bound DNA sequence-selectively (preferring CNG sites and discriminating cytosine methylation), proposed as a basis for epigenetic gene regulation — this is the in-vitro origin of the "tripeptide enters the nucleus and modulates transcription" hypothesis (Fedoreyeva et al., Biochemistry (Moscow), 2011; PMID 22117547; DOI 10.1134/S0006297911110022). Note this was done in HeLa, a cancer cell line, not neurons, and demonstrates binding in a model system — not that this is the physiological mechanism in humans.
• [Animal] In a rat model of methionine-induced prenatal hyperhomocysteinemia, pinealon given to pregnant rats improved offspring spatial learning and reduced ROS accumulation and necrotic cerebellar neurons (Arutjunyan et al., Int J Clin Exp Med, 2012; PMID 22567179). Small single-group rodent study, originating group; no DOI located, PMID verified.
• [In vitro] In aging brain-cortex cell cultures, EDR (and Lys-Glu-Asp) stimulated serotonin expression, proposed to act via the tryptophan hydroxylase (TPH1) gene — the basis for the serotonin/TPH1 mechanistic claim (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2014; PMID 24909721; DOI 10.1007/s10517-014-2496-y).
• [In vitro] In an amyloid-beta model in primary mouse hippocampal neurons, EDR at 200 ng/ml increased mushroom-type dendritic spines by ~71%, restoring the parameter toward normal (related peptide KED gave ~20%) (Kraskovskaya et al., Bulletin of Experimental Biology and Medicine, 2017; PMID 28853087; DOI 10.1007/s10517-017-3847-2). A cell model of Alzheimer's, not an animal or human study.
• [Animal] In 5xFAD transgenic mice, EDR and KED prevented dendritic-spine loss, with molecular modeling identifying candidate promoter binding sites, interpreted as epigenetic neuroprotection (Khavinson et al., Pharmaceuticals (Basel), 2021; PMID 34071923; DOI 10.3390/ph14060515). Open-access and English-language, so verifiable, but still the originating group and not an independent replication.
• [Animal] In 18-month-old aged rats under hypoxia/hypothermia stress, pinealon influenced brain adrenergic and serotonin mediator levels; its effect on free-radical processes and caspase-3 activity was described as weaker than Cortexin's (Mendzheritsky et al., Advances in Gerontology, 2015; PMID 28509493). This Rostov group shares co-author Ryzhak and remains within the Russian bioregulator network rather than being a fully independent Western lab; Russian-language original, no DOI located, PMID verified.

The mechanistic hypothesis (nuclear penetration; SOD2/GPX1/TPH1/PPAR modulation; reduced caspase-3/p53) is consolidated in a [Hypothesis] narrative review by the same group (Khavinson et al., Molecules, 2020; PMID 33396470; DOI 10.3390/molecules26010159) — a review, not primary data.

On human use, be careful. The frequently-repeated [Human] claim that oral pinealon improved memory and EEG alpha-index in patients with TBI consequences and cerebrasthenia does not trace to a primary randomized or blinded trial report; it traces to a Russian-language review by the originating group (Umnov, Lin'kova & Khavinson, Advances in Gerontology, 2013; PMID 24738258), which the 2020 Molecules review in turn summarizes. The specific "72 patients, oral 0.2 mg twice daily for 20–30 days" protocol repeated across vendor blogs could not be located as an independently reported primary trial with stated design, blinding or randomization, so it should not be presented as a clinical trial. Likewise, claims that pinealon is a registered/approved dietary supplement in Russia appear only in commercial vendor sources — no authoritative Russian regulator (Rospotrebnadzor/Roszdravnadzor) registration number or official record was verified. Oral bioavailability, human half-life, and any dosing/safety toxicology figures are repeated in secondary sources but no primary pharmacokinetic or regulatory data was located to verify them. A pinealon-specific melatonin/circadian effect is referenced in secondary sources but could not be confirmed as driven by Glu-Asp-Arg specifically.

Quality, plainly: the evidence is small, largely single-group and under-replicated. Nearly every study traces to Khavinson's institute or its immediate network, the base is in-vitro and rodent (mechanistic and preclinical), and the human evidence is the weakest link — a narrative review, not a verifiable primary trial. Pinealon is not approved by the FDA or EMA, has never been submitted for their review, and has no registered US/EU clinical trial; in the West it is distributed only as a research-use-only reagent. Being sold or studied in Russia is a regulatory and commercial fact, not proof of efficacy. Human efficacy should be treated as unproven at the primary-trial level.